NIH SCIENTIFIC FRAUD INVESTIGATOR WALTER STEWART is on temporary detail to Chairman Dingell's (D-Mich.) House Oversight & Investigations Subcommittee staff. Stewart has been with the subcommittee for about eight months, joining shortly after he appeared at April subcommittee hearings. Stewart's stint with the subcommittee is open-ended. Stewart testified at the subcommittee's April hearings as an expert in the area of uncovering scientific misconduct. For nearly five years, Stewart and NIH colleague Ned Feder, MD, have been involved in researching the accuracy of scientific literature and of scientific misconduct, particularly in NIH-supported research. The two published an article in Nature Jan. 15, 1987, analyzing alleged errors and discrepancies in 18 papers by cardiology researcher John Darsee and co-authors. Stewart and Feder have also written about a study done at MIT and co-authored by Nobel prize-winner David Baltimore. Stewart and Feder are with the National Institute of Diabetes and Digestive and Kidney Diseases. In other cases, the subcommittee is looking into a study done by a former Harvard researcher on the use of a vitamin A (tretinoin) ointment for dry eye syndrome and into the use of diagnostic procedures developed by Duke University scientists.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.
Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
